The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

Strong Market Growth in Recent Years

• The bioinformatics in in vitro diagnostics (IVD) testing market has seen robust growth.
• Market size increased from $87.25 billion in 2023 to $93.02 billion in 2024.
• This growth, with a compound annual growth rate (CAGR) of 6.6%, can be attributed to several factors:
  • Improved healthcare infrastructure.
  • Expansion of biobanks.
  • Rising geriatric population.
  • Government initiatives and funding.
  • Growth of personalized medicine.

Future Market Projections: Continued Expansion

• The market is projected to grow to $121.57 billion by 2028, at a CAGR of 6.9%.
• Key drivers in the forecast period include:
  • Rising prevalence of diseases.
  • Integration of IT in healthcare.
  • Government initiatives and funding.
  • A shift towards personalized medicine.
  • Enhanced awareness among healthcare providers.
  • Decreasing cost of genomic sequencing.

Read More On The Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report 2024 –  https://www.thebusinessresearchcompany.com/report/bioinformatics-in-in-vitro-diagnostics-ivd-testing-global-market-report

Trends Shaping the Future

• Artificial Intelligence (AI) and Machine Learning: Transforming data analysis and diagnostics.
• Next-Generation Sequencing (NGS): Revolutionizing genetic analysis.
• Point-of-Care (POC) Testing: Enhancing accessibility and convenience.
• Cloud Computing and Big Data: Facilitating large-scale data analysis.
• Innovations in Immunochemical Techniques: Improving diagnostic accuracy.

Rising Chronic Diseases Propel Market Growth
Impact of Increasing Cancer Prevalence

• Cancer rates are rising globally, expected to reach 28.4 million cases by 2040, a 47% increase from 2020.
• Factors driving this increase include exposure, lifestyle, and environmental influences.
• Bioinformatics in IVD testing plays a crucial role in cancer diagnostics by:
  • Providing precise, personalized genetic insights.
  • Enhancing early detection.
  • Informing treatment decisions.
  • Improving patient outcomes.

Role of Bioinformatics in Cancer Detection

• Bioinformatics tools in IVD testing allow for comprehensive analysis, aiding in the early detection of cancer.
• This technology supports personalized medicine, tailoring treatment plans based on individual genetic profiles.

Major Players in the Market

• Leading companies in the bioinformatics in IVD testing market include:
  • Siemens Healthineers
  • International Business Machines Corporation
  • Medtronic Inc.
  • Illumina Inc.
  • QIAGEN N.V.
  • PerkinElmer Inc.
  • Bioreference Laboratories Inc.
• These companies are driving innovation and expansion in the market, contributing to its rapid growth.

Revolutionizing Genetic Analysis with NGS Technology
Advancements in Next-Generation Sequencing (NGS)

• Major companies focus on developing next-generation sequencing (NGS) technology.
• NGS allows for rapid sequencing of entire genomes or specific DNA/RNA regions.
• This technology improves:
  • Detection and analysis of genetic mutations.
  • Diagnostic accuracy.
  • Personalized medicine approaches.

Case Study: Illumina’s Innovations

• In May 2022, Illumina Inc. launched the TruSight Oncology Comprehensive (EU) test.
• This pan-cancer companion diagnostic (CDx) identifies cancer patients with neurotrophic tyrosine receptor kinase (NTRK) gene fusions.
• The test aids in targeted therapy, showcasing the power of NGS in cancer treatment.

Accelerating Cancer Diagnosis: Illumina’s Acquisition of GRAIL
Strategic Acquisition for Enhanced Diagnostics

• In August 2021, Illumina Inc. acquired GRAIL to accelerate cancer diagnosis.
• GRAIL specializes in bioinformatics for IVD testing, particularly in cancer detection.
• This acquisition aims to:
  • Speed up patient access to diagnostic tools.
  • Enable the identification of multiple cancer types using a single blood sample.

Regional Insights and Market Segmentation
North America Leading, Asia-Pacific Rising

• North America was the largest region in the bioinformatics in IVD testing market in 2023.
• Asia-Pacific is expected to be the fastest-growing region during the forecast period, driven by:
  • Expanding healthcare infrastructure.
  • Increased government initiatives and funding.
  • Rising demand for personalized medicine.

Market Segmentation

• The bioinformatics in IVD testing market is segmented by:
  • Type: Hardware, Software.
  • Type of Test: Blood-Based Tests, Tissue-Based Tests.
  • Application: Cardiovascular Diseases, Chronic Diseases, Diabetes, Cancer, Other Applications.

Conclusion: A Market Poised for Growth

• The bioinformatics in IVD testing market is set for continued growth, driven by advancements in technology, rising disease prevalence, and increasing focus on personalized medicine.
• As companies innovate and expand, the market will continue to play a critical role in enhancing diagnostic accuracy and improving patient outcomes.

Request for A Sample Of The Global Bioinformatics In In-Vitro Diagnostics (IVD) Testing Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=16629&type=smp